10 Former MiMedx Employees In Non-Compete Suit
Fight Back Against MiMedx Schemes to "Bilk Medicare" and
"Incentivize Fraud" in Counterclaims Filed by Mintz
Attorneys
MARIETTA, Ga., Sept. 11,
2024 /PRNewswire/ -- 10 former employees of MiMedx
Group, Inc. (NASDAQ: MDXG) have now filed counterclaims against the
placental biologics company in response to a non-compete lawsuit
filed by MiMedx earlier this year. Among other allegations,
the employee countersuits assert that in some cases that MiMedx
engaged in "schemes to bilk Medicare and other government and
third-party taxpayers" and that "MiMedx tried to compel its
employees to continue selling a product that the U.S. Food and Drug
Administration determined could not lawfully be marketed without
prior FDA approval." The filings describe the MiMedx suit as
a "blatant intimidation tactic" against former employees who were
"forced to leave" MiMedx as a result of its alleged
wrongdoing.
Specifically, the counterclaims allege that
MiMedx "pressure[d] healthcare providers to treat wounded veterans,
diabetics, chronic wound sufferers, and other patients with
medically unnecessary or unsuitable products—all to the detriment
of patients "that are amongst the most vulnerable populations". Key
filings also allege that MiMedx "engaged in and has
directed members of its sales team including [the defendants] to
engage in, predatory sales practices aimed at increasing its
revenue by incentivizing fraud on the United States government, including
Medicare fraud."
Some of the claims reference a warning letter issued by the FDA
to MiMedx's CEO, Joseph H. Capper,
concerning its AXIOFILL product on December 20, 2023, and assert that former
employees believed "that the company had wasted the sales team's
time claiming that there were no issues regarding AxioFill" even
after receiving the letter, and that MiMedx's "lack of
communication and transparency" regarding the facts were disturbing
and led to them seeking employment elsewhere.
The claims filed by the former employees' attorneys at Mintz and
Fellows Labriola allege that the
employees left MiMedx after "MiMedx tried to compel its
employees to continue selling a product that the U.S. Food and Drug
Administration ('FDA') determined could not lawfully be marketed
without prior FDA approval."
Today's counterclaims come on the heels of complaints filed last
month on behalf of ex-MiMedx employees. To read the LATEST
claims please click below.
To read Logan Richard's claims,
click [HERE]
To read Judi Polacri's claims, click [HERE]
To read Eidrian Garcia's claims, click :[HERE]
To read London Barber's claims, click [HERE]
To read Parker Taylor's claims,
click [HERE]
To read Cole Pearson's claims,
click [HERE]
To read Claudia Nguyen's claims,click [HERE]
To read the PREVIOUS claims please click below.
Jacob Heikkinen
Caralyn Gargan
Lara Whooley
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ex-mimedx-employees-allege--mimedx-pressured-healthcare-providers-to-treat-wounded-veterans-diabetics-chronic-wound-sufferers-and-other-patients-with-medically-unnecessary-or-unsuitable-products-302245440.html
SOURCE Mintz Levin